Search
Arotinolol
go.drugbank.com/drugs/DB09204Investigational[T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]
Sulodexide
go.drugbank.com/drugs/DB06271ApprovedInvestigationalWithdrawnSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Smilagenin
go.drugbank.com/drugs/DB05450InvestigationalSmilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the
Metocurine
go.drugbank.com/drugs/DB01336ApprovedDimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.
PPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Atinumab
go.drugbank.com/drugs/DB17923InvestigationalATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
KDT-3594
go.drugbank.com/drugs/DB17085InvestigationalKDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 ...
D-alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14002ApprovedNutraceuticalVet approvedAlpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements.
AM103
go.drugbank.com/drugs/DB05225ExperimentalIt is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation